These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1045 related items for PubMed ID: 33221125

  • 1. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV, Levin FR, Reilly MP, El-Bassel N.
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [Abstract] [Full Text] [Related]

  • 2. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
    Jaffe K, Slat S, Chen L, Macleod C, Bohnert A, Lagisetty P.
    J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
    [Abstract] [Full Text] [Related]

  • 3. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC, King CA, Englander H, Lovejoy TI, McCarty D.
    Subst Abus; 2022 Aug; 43(1):1251-1259. PubMed ID: 35670778
    [Abstract] [Full Text] [Related]

  • 4. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mhatre-Owens A, Dungan MT, Hagedorn H.
    Subst Abus; 2020 Aug; 41(3):275-282. PubMed ID: 32697170
    [Abstract] [Full Text] [Related]

  • 5. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM.
    JAMA Psychiatry; 2022 Oct 01; 79(10):981-992. PubMed ID: 36044198
    [Abstract] [Full Text] [Related]

  • 6. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
    Johnson K, Hills H, Ma J, Brown CH, McGovern M.
    Am J Drug Alcohol Abuse; 2021 Mar 04; 47(2):220-228. PubMed ID: 33054435
    [Abstract] [Full Text] [Related]

  • 7. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM, Nielsen T, Hoeppner BB, Terplan M, Hansen H, Bernson D, Diop H, Bharel M, Krans EE, Selk S, Kelly JF, Wilens TE, Taveras EM.
    JAMA Netw Open; 2020 May 01; 3(5):e205734. PubMed ID: 32453384
    [Abstract] [Full Text] [Related]

  • 8. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK, Xu KY, Salas J, Bedrick BS, Grucza RA.
    J Gen Intern Med; 2024 Jun 01; 39(8):1342-1348. PubMed ID: 38424347
    [Abstract] [Full Text] [Related]

  • 9. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
    Chan B, Bougatsos C, Priest KC, McCarty D, Grusing S, Chou R.
    Subst Abus; 2022 Jun 01; 43(1):539-546. PubMed ID: 34520702
    [Abstract] [Full Text] [Related]

  • 10. Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island.
    Clark SA, Davis C, Wightman RS, Wunsch C, Keeler LAJ, Reddy N, Samuels EA.
    J Subst Abuse Treat; 2021 May 01; 124():108283. PubMed ID: 33771282
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S, Sun L, Vakkalanka JP.
    Am J Emerg Med; 2024 Aug 01; 82():52-56. PubMed ID: 38795424
    [Abstract] [Full Text] [Related]

  • 12. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C, Sutherland L, Beal L, Terplan M, Latkin C, Clarke JG.
    Addiction; 2020 Nov 01; 115(11):2057-2065. PubMed ID: 32141128
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections.
    Ivasiy R, Madden LM, DiDomizio E, Johnson KA, Machavariani E, Ahmad B, Oliveros D, Ram A, Kil N, Altice FL.
    Drug Alcohol Depend; 2024 Oct 01; 263():112410. PubMed ID: 39159600
    [Abstract] [Full Text] [Related]

  • 17. Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.
    Goedel WC, Shapiro A, Cerdá M, Tsai JW, Hadland SE, Marshall BDL.
    JAMA Netw Open; 2020 Apr 01; 3(4):e203711. PubMed ID: 32320038
    [Abstract] [Full Text] [Related]

  • 18. Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19.
    Livingston NA, Ameral V, Banducci AN, Weisberg RB.
    J Subst Abuse Treat; 2021 Mar 01; 122():108222. PubMed ID: 33303255
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of Perceived Access and Treatment Knowledge on Medication Preferences for Opioid Use Disorder.
    Jaffe K, Patel S, Chen L, Slat S, Bohnert A, Lagisetty P.
    Subst Use Addctn J; 2024 Oct 01; 45(4):706-715. PubMed ID: 38828548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.